 CAMBRIDGE, Mass., Dec. 23, 2022 GLOBE NEWSWIRE Pyxis Oncology, Inc. Nasdaq: PYXS, a clinical stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, reported on December 23, 2022 that Pyxis Oncologys Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 52,560 shares of Pyxis ... The post Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635c4 appeared first on Fo... 